Inivata strikes gold with ‘excellent’ results from lung cancer studies
Cambridge UK liquid biopsy business Inivata has been buoyed by results from two studies of its InVisionFirst-Lung liquid biopsy test for use in advanced non-small cell lung cancer (NSCLC).
The multi-centre studies were conducted in collaboration with 41 key institutions across the United States.
The resulting data, published in JCO Precision Oncology, highlights the potential of Inivata’s first Medicare-reimbursed commercial test to improve delivery of comprehensive tumour genomic profiling.
The studies recruited 264 advanced NSCLC patients and compared the genomic profiling performance of InVisionFirst-Lung versus standard-of-care tissue testing.
The studies showed that Inivata’s liquid biopsy test demonstrated excellent concordance with tissue profiling, with a high level of sensitivity and specificity. Notably, the InVisionFirst-Lung liquid biopsy test was able to detect 26 per cent more actionable alterations versus standard-of-care tissue testing.
More comprehensive testing with InVisionFirst-Lung could lead to increasingly accurate patient stratification and potentially to improved outcomes based on more personalised therapy.
Inivata CEO Clive Morris said: “We are delighted to publish compelling data that highlights the robust clinical validation for InVisionFirst-Lung in patients with advanced non-small cell lung cancer. The data demonstrate the potential of our liquid biopsy technology to help clinicians make more informed treatment decisions for patients with advanced NSCLC.
“Advanced liquid biopsy technologies like our InVision platform are becoming increasingly important for helping to refine and improve the treatment of cancer, particularly in cases where tissue testing is not achievable.”
Dr Ramaswamy Govindan, Professor of Medicine, Washington University School of Medicine, endorsed the technology on the back of the results. He added: “In this multi-centred prospective study, the InVisionFirst-Lung test showed excellent concordance with tissue profiling.
“The detection of an increased percentage of patients with actionable mutations using liquid biopsy demonstrates how this technology can help ensure patients with lung cancer receive the appropriate therapies.
“Using liquid biopsies enables us to make informed treatment decisions in the absence of comprehensive tissue testing, ensuring more NSCLC patients can be treated with the appropriate therapy, improving their chances of durable response and survival.”